A Phase 4 interventional study of CYTALUX™ (pafolacianine) in Gastrointestinal Cancer, Gastric Cancer and Esophageal Cancer, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Cedars-Sinai Medical Center · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 212th largest by planned enrollment of the 245 interventional ones that give a count, is one of 21 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 56 of the 113 other live ones, and was the 294th registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Orlando Health, Inc. · Sites in United States
Ages 18–100
Northwestern University · Sites in United States
Ages 18+
BigHat Biosciences, Inc. · Sites in United States
Ages 18+
Genmab · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 96 · Phase 2 82 · Phase 3 12 · Phase 4 4
First in 1995; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 73 across 497 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 60 across the 245 interventional studies, 172 across the 64 observational. Of the 182 that completed or were terminated, 68 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 316 have an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 4 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Gastrointestinal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511037University of California, IrvinePhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | 2026-11-30 |
| NCT05318027Abramson Cancer Center at Penn MedicineChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06569693University of MiamiDyadic Sleep Study | 2026-12-01 |
| NCT06134687Baylor College of MedicineNovel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection | 2026-12-04 |
Add all 40 to your calendar (.ics) → With an account.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled subjects will be dosed with 0.025 mg/kg CYTALUX™ (pafolacianine) injection intravenously, with the hour-long infusion completing from 1 hour to up to 24 hours prior to imaging for the planned surgery.
Drug: CYTALUX™ (pafolacianine)
All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.
Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging
Determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal) in at least 70% of the patients.
Time frame: 12 months
Number of Lesions
Number of lesions that are simultaneously fluorescence positive and cancer positive.
Time frame: 12 months
Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pafolacianine